This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Apr 2011

Sequella & Maxwell Ink $50M Licensing Pact for TB Treatment

The American biotech company Sequella and Russia’s Maxwell Biotech Venture Fund have signed an agreement on the clinical development and commercialization of an anti-tuberculosis drug.

Rockville, MD-based biotech company Sequella has completed a round of high-fives with leaders of the region's biotech community after inking a licensing pact covering Russia and surrounding states for its mid-stage tuberculosis treatment.


Sequella boasts that the deal is potentially worth up to $50 million, though it didn't brea

Related News